Cosmo (SWX:CMHC) is back in focus after reporting 12 month Phase 3 data for its clascoterone 5% topical solution in male pattern hair loss, highlighting sustained efficacy and a safety profile comparable to vehicle.
See our latest analysis for Cosmo.
Despite the latest clascoterone update putting Cosmo back on investors’ radar, the stock has seen its share price fall 9.35% over the past month and 25.48% over the past quarter. At the same time, the 1 year total shareholder return of 7.43% and 3 year total shareholder return of 43.14% point to a stronger longer term picture than the recent share price weakness suggests.
If this kind of clinical news has you thinking about where else growth stories might emerge in healthcare, it could be worth scanning the market through the 129 healthcare AI stocks
Cosmo now trades a long way below both analyst targets and some intrinsic value estimates. After the recent share price slide, where does a fair value range really sit for this stock?
Most Popular Narrative: 41.8% Undervalued
Cosmo last closed at CHF58.20, while the most followed narrative sets fair value at CHF100. The gap between those two figures is what investors are debating.
Cosmo is a multi vertical life sciences platform. MedTech AI, dermatology, GI pharma and royalties, and CDMO are all valued in a structured sum of the parts exercise, with commercial assets and the pipeline each contributing sizeable portions to the overall equity value.
Curious how that CHF100 fair value comes together. The narrative leans heavily on recurring revenue strength, future margins and a premium pipeline multiple. The detailed sales mix and timing assumptions stay behind the curtain. The full story connects those moving parts into a single target range.
Result: Fair Value of CHF100 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Cosmo still faces clear risks, including the outcome of key trials and any delay or setback in securing new licensing or commercial agreements.
Find out about the key risks to this Cosmo narrative.
Next Steps
Does the split sentiment on Cosmo make you curious about what the data really says? Take a closer look at both sides with the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Cosmo?
If Cosmo has sharpened your focus, do not stop there. The market is full of other potential opportunities that deserve a closer look today.
- Spot potential value opportunities early by scanning the market using the 272 high quality undervalued stocks.
- Strengthen your portfolio resilience with companies filtered through the 294 resilient stocks with low risk scores.
- Hunt for lesser known potential winners by reviewing the screener containing 614 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com